SEC Form 4 · accession 0001193805-16-003191
ADMA BIOLOGICS, INC. · ADMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam S Grossman
Officer — President & CEO · Director
Period of report
May 3, 2016
Accepted (ET)
May 5, 2016 · 7:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001368514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value per shareF1,F2,F3 | May 3, 2016 | P | 200,000 | $6.50 | A | 843,668 | I | Please see Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1580,957 of these shares are held by Hariden, LLC, an entity for which the Reporting Person has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- F2258,700 of these shares are held by Areth LLC, an entity for which the Reporting Person has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- F3These shares are being purchased by Areth LLC, an entity for which the Reporting Person has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.